NEW YORK – Oxford Nanopore Technologies has experienced quality problems with some commercial batches of Flongle flow cells, its most affordable sequencing chips that were released earlier this year, and is trying to scale up production to meet rising demand from users. While dealing with these issues, the company recently announced that it will start offering sequencing products for regulated applications, such as clinical assays and food testing, next year.